<DOC>
	<DOCNO>NCT02195284</DOCNO>
	<brief_summary>This study design assess proportion asthma subject make critical non-critical error make use ELLIPTA® inhaler compare commercially available inhaler device TURBUHALER® , MDI ( metered-dose inhaler ) , DISKUS/ACCUHALER® . This study also assess ease use preference ELLIPTA inhaler commercially available inhaler device . This randomized , open-label , placebo , crossover , multicentre study single visit . The study comprise three sub-studies . Subjects receive inactive treatment ( placebo ) via ELLIPTA inhaler one inhaler device depend sub-study allocate . Only subject naïve ELLIPTA inhaler one inhaler use study include . The study conduct Netherlands UK , comprise one visit . A sufficient number subject ( least 190 ) asthma screen 180 randomize one three sub-studies . Eligible subject allocate one sub-studies follow order depend experience use inhaler ( i.e. , depend inhaler naïve ) . ELLIPTA , DISKUS , ACCUHALER register trademark GSK group company . TURBUHALER register trademark AstraZeneca .</brief_summary>
	<brief_title>To Study Device Attributes Investigating Errors Made Use , Ease Use Preference Among Different Inhalers Subjects With Asthma</brief_title>
	<detailed_description>This non-interventional study observational study therefore field applicable CT.gov observational study design . It would preferential field populate `` applicable '' sample method , time perspective , observational study model n't apply study design .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Informed consent : Subject must give sign dated write informed consent participate ; Subject understands willing , able , likely comply study procedure restriction ; Subject must able read , comprehend , record information Dutch and/or English Age : &gt; =18 year age Gender : Male female subject . Asthma Diagnosis : A diagnosis asthma define National Institutes Health . Comorbidities ( rheumatoid arthritis locomotor problem , visual impairment , depression anxiety ) document relevant inhaler use . Asthma treatment : All subject currently receive treatment asthma . Must naive use ELLIPTA inhaler least one inhaler device . Chronic Obstructive Pulmonary Disease ( COPD ) : Subjects current diagnosis COPD . Contraindications : A history allergy hypersensitivity lactose/milk protein magnesium stearate excipient . Subjects currently participate another randomised pharmacological interventional trial . Inability Read : In opinion investigator , subject unable read and/or would able complete questionnaire understand verbal instruction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Inhaler preference</keyword>
	<keyword>Overall inhaler error</keyword>
	<keyword>DISKUS/ACCUHALER</keyword>
	<keyword>MDI</keyword>
	<keyword>TURBUHALER</keyword>
	<keyword>ELLIPTA</keyword>
	<keyword>Ease use</keyword>
	<keyword>Critical inhaler error</keyword>
</DOC>